Targeting transcriptional control of soluble guanylyl cyclase via NOTCH for prevention of cardiovascular disease

Acta Physiologica
C RippeK Swärd

Abstract

Soluble guanylyl cyclase (sGC) is an effector enzyme of nitric oxide (NO). Recent work has unravelled how levels of this enzyme are controlled, and highlighted a role in vascular disease. We provide a timely summary of available knowledge on transcriptional regulation of sGC, including influences from the NOTCH signalling pathway and genetic variants. It is speculated that hypertension-induced repression of sGC starts a vicious circle that can be initiated by periods of stress, diet or genetic factors, and a key tenet is that reduction in sGC further raises blood pressure. The idea that dysregulation of sGC contributes to syndromes caused by defective NOTCH signalling is advanced, and we discuss drug repositioning for vascular disease prevention. The advantage of targeting sGC expression rather than activity is also considered. It is argued that transcriptional inputs on sGC arise from interactions with other cells, the extracellular matrix and microRNAs (miRNAs), and concluded that the promise of sGC as a target for prevention of cardiovascular disease has increased in recent time.

References

Jan 1, 1986·Nephron·T YokozawaF Koizumi
Apr 1, 1995·The Journal of Clinical Investigation·A A QuyyumiR O Cannon
Jan 1, 1995·Annual Review of Physiology·R Ross
Jul 1, 1993·The American Journal of Physiology·B E RobertsonM T Nelson
Mar 1, 1996·Journal of the American College of Cardiology·S B WilliamsM A Creager
May 1, 1997·The New England Journal of Medicine·A P BurkeR Virmani
Jul 1, 1997·Nature Genetics·T OdaS C Chandrasekharappa
Mar 21, 1998·The Journal of Clinical Investigation·R D RudicW C Sessa
Jun 26, 1998·The EMBO Journal·A PfeiferF Hofmann
Jul 21, 1998·Journal of the American College of Cardiology·M R AdamsD S Celermajer
Sep 22, 1998·The Biochemical Journal·U ZabelH H Schmidt
Mar 3, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K M EmerickD A Piccoli
Feb 13, 2001·Trends in Cell Biology·C Bogdan
Mar 10, 2001·Nature·J P StaschM Schramm
Dec 1, 2001·Free Radical Biology & Medicine·M WeberG Kojda
Nov 21, 2002·The Journal of Biological Chemistry·Stephan KlossAlexander Mülsch
Nov 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Wanda NiedbalaFoo Y Liew
Jan 14, 2003·The Journal of Biological Chemistry·Vincent SauzeauPierre Pacaud
Mar 22, 2003·Blood·Bernhard Nieswandt, Steve P Watson
May 7, 2003·Cell·Francesc MirallesRichard Treisman
Dec 4, 2003·Circulation Research·Renate B Pilz, Darren E Casteel
Aug 3, 2004·Nature Reviews. Drug Discovery·Ted T Ashburn, Karl B Thor
Mar 17, 2005·Frontiers in Bioscience : a Journal and Virtual Library·Renate B Pilz, Kate E Broderick

❮ Previous
Next ❯

Citations

Aug 15, 2019·Protein Science : a Publication of the Protein Society·Andrzej WeichselWilliam R Montfort
Nov 14, 2019·Acta Physiologica·Ralf Mrowka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

© 2022 Meta ULC. All rights reserved